Applications will be accepted until 5pm on the 5th of August 2019 and will be considered by the Rare Disorders Subcommittee at their meeting scheduled for the 24th of September 2019.
- The medicine must have been approved by Medsafe or an approved international regulatory authority for the identified indication;
- The disorder is a clinically defined disorder affecting an identifiable and measurable patient population with a prevalence of less than 1:50,000 in NZ;
- The medicine is only registered for the treatment of the rare disorder, or if it is registered for other disorders (or is part of Phase 3 clinical trials for other disorders), the cumulative prevalence across all indications is still less than 1:50,000 in NZ.
Additionally, applications should still meet the requirements of a full funding application, addressing the Factors for Consideration, as per standard PHARMAC submissions.
For assistance in the preparation of an application to PHARMAC, please contact [email protected]